6.49
-0.07(-1.07%)
Currency In USD
| Previous Close | 6.56 |
| Open | 6.52 |
| Day High | 6.55 |
| Day Low | 6.36 |
| 52-Week High | 23.48 |
| 52-Week Low | 5.41 |
| Volume | 1.32M |
| Average Volume | 1.47M |
| Market Cap | 524.25M |
| PE | -3.21 |
| EPS | -2.02 |
| Moving Average 50 Days | 6.89 |
| Moving Average 200 Days | 13.05 |
| Change | -0.07 |
If you invested $1000 in Kura Oncology, Inc. (KURA) since IPO date, it would be worth $432.67 as of May 02, 2025 at a share price of $6.49. Whereas If you bought $1000 worth of Kura Oncology, Inc. (KURA) shares 5 years ago, it would be worth $441.5 as of May 02, 2025 at a share price of $6.49.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST
GlobeNewswire Inc.
Apr 28, 2025 11:30 AM GMT
– Phase 1 dose-escalation study to evaluate ziftomenib in combination with imatinib in patients with advanced GIST after imatinib failure – – Combination of ziftomenib and imatinib shows robust and durable antitumor activity in imatinib-sensitive and
Kura Oncology to Report First Quarter 2025 Financial Results
GlobeNewswire Inc.
Apr 24, 2025 11:30 AM GMT
SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it w
Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA
GlobeNewswire Inc.
Apr 08, 2025 11:30 AM GMT
– Submission seeks approval for the treatment of adult patients with relapsed or refractory AML with a NPM1 mutation –SAN DIEGO and TOKYO, April 08, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), and Kyowa Kirin Co., Ltd. (TSE